NewAmsterdam Pharma Company N.V. (NAMS) – What Are Researchers Thinking About This Stock?

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been given an average rating of “Moderate Buy” by the thirteen brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is $49.00.

Several research firms recently issued reports on NAMS. BMO Capital Markets assumed coverage on NewAmsterdam Pharma in a research report on Monday, July 20th. They set an “outperform” rating and a $58.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Jefferies Financial Group restated a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. Royal Bank Of Canada dropped their price target on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a research note on Monday, October 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $52.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, September 8th.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $21.58 on Wednesday. NewAmsterdam Pharma has a 52-week low of $20.91 and a 52-week high of $42.21. The firm has a market capitalization of $2.58 billion, a PE ratio of -9.99 and a beta of 0.10. The stock has a fifty day simple moving average of $24.91 and a two-hundred day simple moving average of $29.95.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. The business had revenue of $3.70 million for the quarter, compared to the consensus estimate of $2.83 million. On average, sell-side analysts forecast that NewAmsterdam Pharma will post -1.82 EPS for the current fiscal year.

Insider Activity at NewAmsterdam Pharma

In other news, insider Johannes Kastelein sold 125,000 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $26.91, for a total value of $3,363,750.00. Following the transaction, the insider owned 69,302 shares of the company’s stock, valued at approximately $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Davidson bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The shares were bought at an average price of $22.65 per share, with a total value of $226,500.00. Following the transaction, the chief executive officer owned 792,923 shares of the company’s stock, valued at $17,959,705.95. The trade was a 1.28% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders sold a total of 281,846 shares of company stock worth $7,847,619 over the last ninety days. 12.74% of the stock is owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

Several hedge funds have recently bought and sold shares of NAMS. Engineers Gate Manager LP bought a new position in NewAmsterdam Pharma during the second quarter valued at approximately $662,000. Squarepoint Ops LLC grew its holdings in NewAmsterdam Pharma by 113.9% during the 2nd quarter. Squarepoint Ops LLC now owns 92,026 shares of the company’s stock valued at $3,119,000 after buying an additional 49,005 shares in the last quarter. Arizona State Retirement System increased its stake in NewAmsterdam Pharma by 34.6% in the 2nd quarter. Arizona State Retirement System now owns 16,656 shares of the company’s stock worth $564,000 after acquiring an additional 4,281 shares during the last quarter. Frazier Life Sciences Management L.P. increased its stake in NewAmsterdam Pharma by 6.8% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock worth $613,033,000 after acquiring an additional 1,145,128 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of NewAmsterdam Pharma by 84.4% during the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock worth $27,115,000 after acquiring an additional 387,698 shares in the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company’s lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities.

Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia.